Anne Barmettler, MD
Ophthalmology · Bronx, NYNPI 1336383538
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,248 of the $4,319 with a category attached, or 75.2%. 13 manufacturers reported payments, led by Lensar, Inc. at 28.8% of the total. Reporting peaked in 2021 at $1,665 and has fallen 81.1% since, to $314 in 2025.
Across 31 payments — averaging $139.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$1K
- Amgen$1K
- Biotissue Holdings Inc.$286
- Aerie Pharmaceuticals, Inc.$249
- Kerecis Limited$240
- Ivantis, Inc$208
- plus $877 from 7 others
What the payments were for
- Consulting fees$651%
- Travel & lodging$84119%
- Food & beverage$3,24875%
- Other$1664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 1 | $1,244 |
| Amgen(2 entities) | 15 | $1,216 |
| Biotissue Holdings Inc. | 2 | $286 |
| Aerie Pharmaceuticals, Inc. | 2 | $249 |
| Kerecis Limited | 2 | $240 |
| Ivantis, Inc | 2 | $208 |
| Integra Lifesciences Corporation | 1 | $166 |
| Sight Sciences, Inc. | 1 | $150 |
| AbbVie | 1 | $147 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Oyster Point Pharma, Inc. | 1 | $115 |
| Ocular Therapeutix, Inc. | 1 | $95 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$1,244
- Kerecis SurgiClose$623
- Rocklatan$249
- Rhopressa$249
- ACell$166
- Kerecis GraftGuide$156
- OMNI(R) SURGICAL SYSTEM (US)$150
- XEN GLAUCOMA TREATMENT SYSTEM$147
- Hydrus Microstent$129
- Syfovre$125
- TYRVAYA$115
How this compares
$4,319 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 209 | $2,313 |
| ErythromycinErythromycin Base | 12 | $148 |
| Methylprednisolone | 16 | $72 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bronx
- Nikola RagusaBronx$81K
- Neil PatelBronx$81K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.